Mark T Barrila

Title: Mark T Barrila: Innovator in Glycogen Phosphorylase Inhibitors

Introduction

Mark T Barrila is a notable inventor based in East Lyme, Connecticut. He has made significant contributions to the field of medicinal chemistry, particularly in the development of glycogen phosphorylase inhibitors. His work is crucial for addressing various metabolic diseases.

Latest Patents

Mark T Barrila holds a patent for "Processes and intermediates for preparing glycogen phosphorylase inhibitors." This invention provides novel processes and intermediates that are useful in the preparation of certain N-(indole-2-carbonyl)-β-alaninamide compounds. These compounds serve as glycogen phosphorylase inhibitors, which are beneficial in treating diseases such as hypercholesterolemia, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, diabetes, diabetic cardiomyopathy, infection, tissue ischemia, myocardial ischemia, and in inhibiting tumor growth. He has 1 patent to his name.

Career Highlights

Mark T Barrila is currently employed at Pfizer Corporation, a leading global pharmaceutical company. His role involves research and development in the area of drug discovery, focusing on innovative solutions for complex health issues.

Collaborations

Throughout his career, Mark has collaborated with esteemed colleagues, including Frank R Busch and Michel A Couturier. These partnerships have enhanced the research and development process, leading to significant advancements in their field.

Conclusion

Mark T Barrila's contributions to the development of glycogen phosphorylase inhibitors highlight his importance in the pharmaceutical industry. His innovative work continues to pave the way for new treatments for various diseases.